To evaluate the efficacy and safety of sitagliptin for the long-term treatment of type 2 diabetes

To evaluate the efficacy and safety of sitagliptin for the long-term treatment of type 2 diabetes - To evaluate the efficacy and safety of sitagliptin for the long-term treatment of type 2 diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000038459

Enrollment

Registered

2019-11-01

Start date

2008-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

Active treatment with sitagliptin 50mg/day for 10 years Active treatment except all of DPP-4 inhibitors for 10 years

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Type 2 diabetes 2) eGFR over 30ml/min/1.73m2 3) Diet end exercise are well performed 4) Understanding of the study procedures and consenting to it by signatures

Exclusion criteria

Exclusion criteria: 1) Pregnant or being pregnant within the study 2) Contraindication with sitagliptin

Design outcomes

Primary

Measure	Time frame
Fasting blood glucose and HbA1c are set to be measured at baseline and once at 3 months for 10 years.	—

Secondary

Measure	Time frame
Body Mass Index (BMI), blood pressure, albumine creatinine ratio (ACR), lipid and liver function are set to be measured at baseline and once at 3 months for 10 years.	—

Countries

Japan

Contacts

Public ContactSachiko Hattori

Foundation Health Medicine Association Tohto Clinic Department of Diabetes and Metabolism

s-hattori@kenkoigaku.or.jp03-3239-0301

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026